Camp4 Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2023
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Revenue	3.5	0.65	0.35	-
Revenue Growth (YoY)	436.50%	86.29%	-	-
Gross Profit	3.5	0.65	0.35	-
Selling, General & Admin	17.36	14.92	11.61	10.23
Research & Development	38.2	38.82	40.62	34.77
Other Operating Expenses	0.49	-	-	-
Total Operating Expenses	56.05	53.74	52.23	45
Operating Income	-52.56	-53.09	-51.88	-45
Interest Income	2.17	1.33	2.81	0.9
Other Non-Operating Income (Expense)	-30.02	-0.03	-0.22	-0.1
Total Non-Operating Income (Expense)	-27.85	1.3	2.59	0.81
Pretax Income	-80.4	-51.79	-49.29	-44.19
Net Income	-80.4	-51.79	-49.29	-44.19
Net Income to Common	-80.4	-51.79	-49.29	-44.19
Shares Outstanding (Basic)	30	5	0	0
Shares Outstanding (Diluted)	30	5	0	0
Shares Change (YoY)	547.76%	1087.44%	10.71%	-
EPS (Basic)	-2.65	-11.04	-124.80	-123.87
EPS (Diluted)	-2.65	-11.04	-124.80	-123.87
Shares Outstanding	51.9	20.15	0.46	0.36
Free Cash Flow	-29.83	-46	-44.83	-42.57
Free Cash Flow Per Share	-0.98	-9.81	-113.51	-
Gross Margin	100.00%	100.00%	100.00%	-
Operating Margin	-1502.43%	-8142.33%	-14822.57%	-
Profit Margin	-2298.54%	-7943.40%	-14083.14%	-
FCF Margin	-852.83%	-7055.67%	-12809.43%	-
EBITDA	-50.92	-51.39	-50.2	-44.12
EBITDA Margin	-1455.57%	-7882.21%	-14343.14%	-
EBIT	-52.56	-53.09	-51.88	-45
EBIT Margin	-1502.43%	-8142.33%	-14822.57%	-

Updated Dec 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q